Cancer suicide gene therapy: a patent review

Navarro-Marchal, Saúl A.; Carrillo, Esmeralda; Griñán‐Lisón, Carmen; Martín, Ángel G.; Perán, Macarena; Marchal, Juan Antonio; Boulaiz, Houría

doi:10.1080/13543776.2016.1211640

Cited by 48 publications

(39 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The concept of suicide gene therapy was originally proposed for cancer treatment. Consist in inserting in tumor cells a gene encoding a cytotoxic protein by applying two main strategies: (i) direct gene therapy, by introducing in tumor cells a toxin gene that reduce the viability of the cells, (ii) indirect gene therapy, by introducing a gene encoding an enzyme into tumor cells that is able to convert a non-toxic prodrug into a cytotoxic drug [25,118,119]. The first proposal of suicide gene therapy was made in 1983 by inserting in BALB/c murine cell lines the herpes virus thymidine kinase gene, and then generate tumors with these cells in BALB/c mice [120,121].…”

Section: Suicide Genesmentioning

confidence: 99%

Gene Therapy in Cancer Treatment: Why Go Nano?

et al. 2020

View full text Add to dashboard Cite

The proposal of gene therapy to tackle cancer development has been instrumental for the development of novel approaches and strategies to fight this disease, but the efficacy of the proposed strategies has still fallen short of delivering the full potential of gene therapy in the clinic. Despite the plethora of gene modulation approaches, e.g., gene silencing, antisense therapy, RNA interference, gene and genome editing, finding a way to efficiently deliver these effectors to the desired cell and tissue has been a challenge. Nanomedicine has put forward several innovative platforms to overcome this obstacle. Most of these platforms rely on the application of nanoscale structures, with particular focus on nanoparticles. Herein, we review the current trends on the use of nanoparticles designed for cancer gene therapy, including inorganic, organic, or biological (e.g., exosomes) variants, in clinical development and their progress towards clinical applications.

show abstract

Section: Suicide Genesmentioning

confidence: 99%

Gene Therapy in Cancer Treatment: Why Go Nano?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Suicide gene therapy includes two strategies: expressing pro-apoptotic proteins or toxin proteins to kill tumor cells directly and using prodrug-activating systems to kill tumor cells indirectly [138]. Engineered OVs can express proapoptotic proteins or toxin proteins to directly kill tumor cells, such as tumor necrosis factor-related apoptosisinducing ligand (TRAIL) [139,140] and apoptin [141].…”

Section: Suicide Genementioning

confidence: 99%

Development of oncolytic virotherapy: from genetic modification to combination therapy

et al. 2020

View full text Add to dashboard Cite

Oncolytic virotherapy (OVT) is a novel form of immunotherapy using natural or genetically modified viruses to selectively replicate in and kill malignant cells. Many genetically modified oncolytic viruses (OVs) with enhanced tumor targeting, antitumor efficacy, and safety have been generated, and some of which have been assessed in clinical trials. Combining OVT with other immunotherapies can remarkably enhance the antitumor efficacy. In this work, we review the use of wild-type viruses in OVT and the strategies for OV genetic modification. We also review and discuss the combinations of OVT with other immunotherapies.

show abstract

“…Suicide gene therapy is a strategy in which death inducing transgenes, called suicide genes, are introduced into cancer cells. There are two types of suicide genes: genes that encode toxic molecules to the cell, and genes that encode for enzymes not found in mammals, that convert an inactive substance into toxic metabolites [79,80]. Different gene-directed enzyme prodrug systems such as cytosine deaminase (CD)/5-flurocytosine (5-FC), herpes simplex virus thymidine kinase (HSV-TK)/ganciclovir enzyme (GCV) [81], nitroreductase (NTR)/CB1954 [82], and uracil phosphoribosyltransferase (UPRT)/5FU [83] have been used as therapeutic weapons in cervix cancer.…”

Section: Suicide Gene Therapymentioning

confidence: 99%

Targeted Gene Delivery Therapies for Cervical Cancer

Ayén

Martínez

Boulaiz

2020

Cancers

Self Cite

View full text Add to dashboard Cite

Despite being largely preventable through early vaccination and screening strategies, cervical cancer is the most common type of gynecological malignancy worldwide and constitutes one of the leading causes of cancer deaths in women. Patients with advanced or recurrent disease have a very poor prognosis; hence, novel therapeutic modalities to improve clinical outcomes in cervical malignancy are needed. In this regard, targeted gene delivery therapy is presented as a promising approach, which leads to the development of multiple strategies focused on different aspects. These range from altered gene restoration, immune system potentiation, and oncolytic virotherapy to the use of nanotechnology and the design of improved and enhanced gene delivery systems, among others. In the present manuscript, we review the current progress made in targeted gene delivery therapy for cervical cancer, the advantages and drawbacks and their clinical application. At present, multiple targeted gene delivery systems have been reported with encouraging preclinical results. However, the translation to humans has not yet shown a significant clinical benefit due principally to the lack of efficient vectors. Real efforts are being made to develop new gene delivery systems, to improve tumor targeting and to minimize toxicity in normal tissues.

show abstract

Cancer suicide gene therapy: a patent review

Cited by 48 publications

References 27 publications

Gene Therapy in Cancer Treatment: Why Go Nano?

Gene Therapy in Cancer Treatment: Why Go Nano?

Development of oncolytic virotherapy: from genetic modification to combination therapy

Targeted Gene Delivery Therapies for Cervical Cancer

Contact Info

Product

Resources

About